Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Bioengineered T cells for Leukaemia and Lymphoma
University of Skövde, School of Life Sciences.
2011 (English)Independent thesis Advanced level (degree of Master (One Year)), 20 credits / 30 HE creditsStudent thesis
Abstract [en]

Cancer immunotherapy is a promising tool for treatment of malignancies. However, there are still hindrances that need to be overcome. Chimeric antigen receptors have the ability to direct immune cytotoxic cells towards tumour-associated antigens in major histocompatibility complex-independent manner. In this study 2 generations of such receptor-bearing T cells, against the CD19 B-cell marker, were investigated for treatment of chronic lymphocytic leukaemia. The 2 nd generation   of this genetically engineered T cell contains CD3ζ  and CD28 intracellular domain, while the third generation has CD137 (4-1BB) in addition. Previous studies have demonstrated advantages of 2 nd  generation chimeric antigen receptor T cells  compared with 1 st generation. In this project the 2 nd and 3 rd generation T   cells  were compared for transduction efficiency, phenotype, proliferative capacity and cytotoxicity in response to antigen from a malignant B cell line. The analysis of transduction showed similar transduction efficiency for both types of chimeric  antigen receptor. However, the data from T cell phenotyping and cytotoxic analysis could not be used for drawing any conclusion, because of too little amount of samples and subsequently, lack of statistical analysis. Further, the proliferative capacity was similar between all transduced T-cell groups and did not give any   conclusive data. The next step will be to stimulate the 2 nd and 3 rd generation T cells with autologous target cells and follow them for a longer time since  allogeneic tumour cell lines trigger an alloreactivity that may mask the different activation states that may occur in the two T cell products.

Place, publisher, year, edition, pages
2011. , 21 p.
National Category
Immunology
Identifiers
URN: urn:nbn:se:his:diva-5593OAI: oai:DiVA.org:his-5593DiVA: diva2:507756
Subject / course
Molecular Biology
Educational program
Molekular Biology - Master's Programme
Uppsok
Medicine
Supervisors
Examiners
Available from: 2012-03-07 Created: 2012-03-06 Last updated: 2012-03-07Bibliographically approved

Open Access in DiVA

Master thesis report(3173 kB)470 downloads
File information
File name FULLTEXT01.pdfFile size 3173 kBChecksum SHA-512
0de000279257e98675b2b2497caeed6be611d790c0d1d68cf7cc55596e316caa8c53110812eadf6c6b67bc42dce1b1465d548a3b117f5c2ce4e9f8a640db53c0
Type fulltextMimetype application/pdf

By organisation
School of Life Sciences
Immunology

Search outside of DiVA

GoogleGoogle Scholar
Total: 470 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 158 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf